ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2689

Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis

Lynn Fussner1, Ivan Bilic2, Carol McAlear3, David Cuthbertson4, Jie Cheng5, Elise Chen5, Markus Weiller2, Ulrich Specks6 and Peter Merkel3, and for the Vasculitis Clinical Research Consortium, 1The Ohio State University, Columbus, OH, 2Takeda Pharmaceuticals, Vienna, Austria, 3University of Pennsylvania, Philadelphia, PA, 4University of South Florida, Tampa, FL, 5Takeda Pharmaceuticals, Cambridge, MA, 6Mayo Clinic, Rochester, MN

Meeting: ACR Convergence 2024

Keywords: ANCA associated vasculitis, Biomarkers, cytokines, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 19, 2024

Title: Abstracts: Vasculitis – ANCA-Associated II

Session Type: Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). It has been proposed that the functionality of A1AT is decreased in inflammatory conditions. This study aimed to gain insight into function of A1AT in AAV, including the relationships of A1AT genotype, and functional activity of A1AT, with targeted biomarkers and disease activity in AAV.

Methods: Clinical data and peripheral blood samples were examined from 250 participants with AAV in a longitudinal cohort, and 80 healthy control individuals. Among those with AAV, 170 with wild-type (WT) A1AT genotype (MM) and 80 with mutant (mut) A1AT genotype (MS, MZ, SS, SZ, or ZZ) with available samples during active disease and remission were selected. Comprehensive analyses were performed, including A1AT total and functional levels, markers of neutrophil activation, and cytokines/chemokines.

Results: Participants with mut A1AT genotype were younger at diagnosis of AAV than those with WT A1AT genotype (Table 1). Among participants with AAV and WT A1AT genotype, 66.5% were PR3-ANCA positive and 26.5% were MPO-ANCA positive during their disease course, as compared to 73.8% and 17.5%, respectively, among those with mut A1AT genotype. Birmingham Vasculitis Activity Score/WG during active visits, and Disease Extent Index are presented in Table 1. Functional A1AT was higher with WT A1AT genotype than with mut genotype during both active disease (p < 0.01) and remission (p < 0.01), and higher among participants with AAV and WT A1AT genotype than among healthy subjects (p < 0.01; Figure 1). Total and functional A1AT aligned with genotype and were consistently lower among those with Z alleles . Cytokine and chemokine levels are presented in Figure 2. During active AAV, levels of proinflammatory cytokines IL-8 and IL-6 were similar across the A1AT genotype subgroups. The decline of these cytokines during remission of AAV was more distinct among those with WT A1AT genotype than those with mut genotype. In contrast, levels of IL-1α and IL-13 were more affected among those with mut genotype than those with WT A1AT genotype, resulting in significant increased levels during active disease (p=0.05 and p < 0.01, respectively). Levels of IL-8 and IL-6 among healthy control subjects were lower than those with WT A1AT genotype during remission (p < 0.01 and p < 0.01, respectively), but IL-1α and IL-13 were similar. During active AAV and remission, levels of the anti-inflammatory cytokine IL-10 were slightly higher among those with WT A1AT genotype than those with mut genotype (p=0.07 and p=0.20, respectively). By comparison, mean IL-10 among healthy subjects was lower than among those with WT A1AT genotype in remission (p < 0.01).

Conclusion: A1AT genotype among people with AAV is associated with differences in age at diagnosis and clinical diagnosis. A1AT antigen levels and activity reflect A1AT genotypes and act as acute-phase reactants, but are not associated with disease status.

Supporting image 1

Supporting image 2

Figure 1. Plasma from patients with ANCA-associated vasculitis (AAV) during remission (A, B) and active disease (B), and HC: Alpha_1 antitrypsin (A1AT) activity measured by elastase complex formation immunosorbent assay. AAV included wild-type genotype (MM, N=170), and mutant genotypes (MS, N=46; MZ, N=26; SS, N=3; SZ, N=1; ZZ, N=4). Activity was also compared to total A1AT antigen (AG) levels, measured by ELISA, with findings for “specific activity” similar to those presented here (data not shown).

Supporting image 3

Figure 2. Cytokine levels were measured by high-multiplex immunoassay in plasma from healthy control subjects and from patients with ANCA-associated vasculitis (AAV) with (insufficient) or without (sufficient) alpha_1 antitrypsin (A1AT) deficiency alleles, during AAV remission or active disease, and healthy control subjects. Select results are presented here as normalized protein expression (NPX, log2).


Disclosures: L. Fussner: Amgen, 2, Takeda, 12, Fudning to VCRC (collaborative body); I. Bilic: Takeda, 3; C. McAlear: None; D. Cuthbertson: None; J. Cheng: Takeda, 3; E. Chen: Takeda, 3; M. Weiller: Takeda, 3; U. Specks: Amgen, 2, 5, Argenx, 2, AstraZeneca, 1, 2, 5, Boehringer-Ingelheim, 1, 2, Bristol-Myers Squibb(BMS), 5, CSL Vifor, 1, Genentech, 5, GlaxoSmithKline(GSK), 5, Northstar Medical Radioisotopes, 5, Novartis, 5, NS Pharma, 5; P. Merkel: AbbVie/Abbott, 2, 5, Amgen, 2, 5, argenx, 2, AstraZeneca, 2, 5, Boehringer Ingelheim, 3, 5, Bristol Myers Squibb, 2, 5, Cabaletta, 2, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 5, Electra, 5, EMDSerano, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GSK, 2, 5, HiBio, 2, Immagene, 2, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Kyverna, 2, Magenta, 2, MiroBio, 2, Neutrolis, 2, Novartis, 2, NS Pharma, 2, Pfizer, 2, Q32, 2, 11, Regeneron, 2, Sanofi, 5, Sparrow, 2, 11, Takeda, 2, 5, Talaris, 2, UpToDate, 9, Visterra, 2.

To cite this abstract in AMA style:

Fussner L, Bilic I, McAlear C, Cuthbertson D, Cheng J, Chen E, Weiller M, Specks U, Merkel P. Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/characterization-of-alpha-1-antitrypsin-function-in-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-alpha-1-antitrypsin-function-in-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology